Evolva’s EV-077 achieved objectives in first group of patients in Phase IIa trial
20-Aug-2012 -
Evolva Holding SA announced top-line results for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids.The initial analysis shows promising efficacy data, indicating that 300mg EV-077 given orally ...
Evolva
phase IIa studies
type 2 diabetes